Several potent and selective NAMPT inhibitors have been developed (e.g., FK866 and CHS-828), which exhibit strong anti-tumor activity in in vitro and in vivo tumor models by efficiently lowering NAD production in a dose- and time-dependent manner. The gene discussed is NAMPT; the disease is neoplasm.